UNCY stock rises after a class action filing and a reverse split

Published on 09/21/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UNCY stock traded at USD 4.80 on September 21, 2026, with market cap at USD 131.487 million. Newsfile said the stock fell 39.1 percent to USD 4.69 on June 30, 2026 after an FDA CRL.

UNCY, US90467V1098, Illustration mit AI erstellt.

Unicycive Therapeutics stock (ISIN US90467V1098) traded at USD 4.80 on September 21, 2026, with a market capitalization of USD 131.487 million. The latest company-linked catalyst in the search set was a September 21, 2026 class action notice that said Unicycive Therapeutics, Inc. (UNCY) faced claims tied to a June 30, 2026 FDA complete response letter and a 39.1 percent drop to USD 4.69 on that day.

Legal risk stays in view

According to AP News on September 21, 2026, Kaplan Fox said investors who bought Unicycive securities between December 29, 2025 and June 29, 2026 may move for lead-plaintiff status by November 2, 2026. The same notice said Unicycive disclosed a complete response letter from the FDA on June 30, 2026.

The filing also said the June 30, 2026 reaction pushed the stock down USD 3.01 to USD 4.69, or 39.1 percent, on unusually heavy trading volume. That is the sharpest concrete move in the current result set.

Reverse split adds context

According to Robinhood, Unicycive Therapeutics, Inc. completed a 1-for-10 reverse split, meaning shareholders now hold 1 share for every 10 shares previously held. For investors, that makes the post-split quote of USD 4.80 on September 21, 2026 easier to read against the June 30, 2026 close of USD 4.69.

UNCY near USD 4.80

UNCY stock was last quoted at USD 4.80 on Nasdaq on September 21, 2026, with market cap at USD 131.487 million. The June 30, 2026 close of USD 4.69 remains the key reference point in the current news set.